

CDSCO Clears India's First Dengue Vaccine

India's Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation for the Dengue Tetravalent Vaccine (Qdenga).

Qdenga is a recombinant live attenuated dengue vaccine approved for individuals aged 4 to 60 years.

KEY EXAM POINTS

- The **Central Drugs Standard Control Organisation (CDSCO)** has approved India's **first dengue vaccine**, named **Qdenga**.
- The vaccine is indicated for individuals aged **4 to 60 years** after rigorous evaluation.
- Qdenga is a **Dengue Tetravalent Vaccine (Live, Attenuated)**, manufactured by **Takeda GmbH, Germany**.
- **Takeda Biopharmaceuticals India Pvt. Ltd.** will be responsible for **importing** the vaccine into India.
- The recommended immunisation schedule involves **two doses** of **0.5 ml** each, administered at a **three-month interval**.
- The **Union Health Ministry** stated that approval was granted after a comprehensive scientific evaluation of the vaccine's **quality, safety, and efficacy**.

STATICS & SYLLABUS FOCUS

The Central Drugs Standard Control Organisation (**CDSCO**) is the **national regulatory body** for Indian pharmaceuticals and medical devices, operating under the **Ministry of Health and Family Welfare**.

Dengue is a mosquito-borne **viral infection** caused by the **dengue virus (DENV)**, primarily transmitted by **Aedes aegypti mosquitoes**.

Live attenuated vaccines use a **weakened form of the virus** or bacteria to stimulate an immune response without causing severe disease.

The **National Vector Borne Disease Control Programme (NVBDP)** in India focuses on preventing and controlling vector-borne diseases, including **dengue**.

Tamil Nadu actively implements public health measures, such as '**Nilavembu Kudineer**' distribution, to control **dengue outbreaks**.

The **World Health Organization (WHO)** provides global guidance and strategies for **dengue prevention and control**, including vaccine recommendations.

Takeda is a **global pharmaceutical company** headquartered in **Japan**, known for its research and development in various therapeutic areas.

REVISION FLASHCARD

CDSCO approved Qdenga, India's first dengue vaccine, for ages 4-60 years.

Syllabus Relevance: High

Free School Books

Read and study school textbooks for free on the ESSAAR Academy platform.

School Books: essaaracademy.in/school-books

